Kalb, Birgit http://orcid.org/0000-0002-3104-6736
Meixner, Lara
Heller, Stephanie
Dölle-Bierke, Sabine
Roll, Stephanie
Tissen-Diabaté, Tatjana
Lau, Susanne
Forslund, Sofia
Marenholz, Ingo
Lee, Young-Ae
Thiel, Andreas
Babina, Magda
Scheffel, Jörg
Worm, Margitta
Beyer, Kirsten
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (409525714)
Charité - Universitätsmedizin Berlin
Article History
Received: 9 December 2023
Accepted: 12 April 2024
First Online: 19 April 2024
Declarations
:
: The trial was approved by the Ethics Committee of Charité – Universitätsmedizin Berlin (REC reference EA2/032/19) on 12 October 2022 prior to the start of recruitment. All parents give their full consent before their children are enrolled in the trial. The written informed consent must be given by both the mother and father or the legal representatives.
: Not applicable.
: BK received consultation fees from Viatris. KB reports grants/research supports from Aimmune, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, and Infectopharm and honoraria or consultation fees from Aimmune, Bencard, Danone/Nutricia/Milupa, DBV, Hipp, Hycor, Infectopharm, Jenapharma, Mylan/Meda, Nestle, Novartis, and Thermo Fisher outside of the submitted work. MW declares the receipt of honoraria or consultation fees from the following companies: ALK-Abelló Arzneimittel GmbH, Mylan Germany GmbH, Leo Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Regeneron Pharmaceuticals, DBV Technologies S.A, Stallergenes GmbH, HAL Allergie GmbH, Allergopharma GmbH & Co.KG, Bencard Allergie GmbH, Aimmune Therapeutics UK Limited, Actelion Pharmaceuticals Deutschland GmbH, Novartis AG, Biotest AG., AbbVie Deutschland GmbH & Co. KG, and Lilly Deutschland GmbH. All other authors declare that they have no competing interests.